how do you spell lasix Antibody drug conjugate approved for treatment of triple negative breast cancer Results from the phase lll ASCENT trial showed that the antibody drug conjugate sacituzumab govitecan, given as a third line treatment, can benefit those with metastatic triple negative breast cancer in both progression free survival and overall survival